Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
paolo tarantino
Feb 18, 2024, 10:00 |
Blog
Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: “How…
Feb 15, 2024, 18:33 |
Blog
Paolo Tarantino: So glad to join outstanding colleagues and friends for productive discussions on the evolving treatment landscape for breast cancer at JSMO24
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared an X post by Kazuki…
Feb 12, 2024, 15:36 |
Blog
Paolo Tarantino: Important update of the ABC trials
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: "Important…
Feb 11, 2024, 15:45 |
Blog
Paolo Tarantino: In a large RW cohort we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: “In…
Feb 10, 2024, 08:06 |
Insight
Paolo Tarantino: Final OS from BROCADE3 phase 3 trial
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: "Final…
Feb 8, 2024, 17:54 |
Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Feb 8, 2024, 05:08 |
Insight
Paolo Tarantino: From no anti-HER2 drugs to a plethora of emerging options
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on Twitter/X: "From no…
Feb 1, 2024, 17:31 |
Insight
Paolo Tarantino: Any agnostic approval should not stop efforts in biomarker discovery for ADCs
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: "Of…
Feb 1, 2024, 15:19 |
Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 29, 2024, 10:53 |
Insight
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard…
10
11
12
13
14
All:
206
Posts:
111 - 120
OncoDaily Announces Strategic Partnership with the Asian Fund for Cancer Research Limited (AFCR)
Peyo the Therapy Horse: Comforting Terminally Ill Patients Through Horse Therapy.
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 3
Small Bowel Cancer: Symptoms & Causes, Types, Diagnosis and Treatment
Mikkael A. Sekeres, Candidate for Secretary of ASH
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube